New Delhi: Indian regulator Central Drugs Standard Control Organization (CDSCO) has given permission to drugmaker Cipla to distribute and sell an inhaled insulin called Afrezza in the country. Afrezza is developed by MannKind Corporation and is used to improve glycemic control, especially for adult patients with diabetes.
This new drug will reduce the need for diabetics to take insulin injections, and it may be a better option for those who have a fear or problem with needles. Cipla aims to make this inhaler insulin more accessible so that millions of people can take better control of their health.
What is Afrezza and how does it work?
Afrezza is a fast-acting insulin that is taken by inhaler. Currently, insulin is given as an injection, but Afrezza is taken before meals and goes directly into the lungs, where it dissolves rapidly and delivers insulin into the blood. Cipla says that Afrezza starts showing its effect in just 12 minutes of taking it and controls the rapid rise in blood sugar levels. Its effect lasts for about two to three hours and is similar to the effect of insulin.
Company Objective
Cipla Managing Director and Global CEO Umang Vohra said, “We are introducing a convenient solution for people suffering from diabetes which will be especially beneficial for those who are afraid of needles or are not able to use them properly. Can.” He said that this will help in controlling diabetes.
Afrezza has been used in the US for 10 years.
Afrezza has been available in the US for more than 10 years and thousands of patients there are benefiting from it. Now Mankind Corporation will supply Afrezza to Cipla and Cipla will sell it in the Indian market. Afrezza’s arrival in India can give a new direction to the methods of diabetes treatment and can become a new option for millions of diabetic patients in India.
